P005: Variability in Vedolizumab Exposure between Patients with Inflammatory Bowel DiseaseECCO '16 Amsterdam
2016
P006: Correlation of small intestinal permeability, faecal calprotectin and barrier genes in multiple-affected families with inflammatory bowel diseaseECCO '16 Amsterdam
2016
P007: IL-36 α expression is elevated in ulcerative colitis and promotes colonic inflammationECCO '16 Amsterdam
2016
P008: Targeting of TSLP by miR-31 may play an important role in mucosal healing, in ulcerative colitis.ECCO '16 Amsterdam
2016
P009: Lipid biomarkers to diagnose Crohn’s disease using metabonomic profiling approach in serum and faeces.ECCO '16 Amsterdam
2016
P010: Infliximab skews macrophages towards an IL10-high/IL12p40-low phenotype in an Fc region dependent mannerECCO '16 Amsterdam
2016
P011: Distinct inflammatory signatures in primary sclerosing cholangitis associated with inflammatory bowel diseaseECCO '16 Amsterdam
2016
P012: MAIT cell activation reflects mucosal inflammation in ulcerative colitisECCO '16 Amsterdam
2016
P013: Automated image analysis in the diagnosis of microscopic colitis: validation and implications for diagnosis and researchECCO '16 Amsterdam
2016
P014: Tofacitinib and a selective Janus kinase 1 inhibitor are equally potent in suppressing human macrophage function and T-cell proliferationECCO '16 Amsterdam
2016
P015: Interaction between enteric glia and myeloid cells as critical players in intestinal immune homeostasis.ECCO '16 Amsterdam
2016
P016: Guggulsterone ameliorates colitis by suppressing TREM-1 hyperactivation and modulating macrophage phenotypesECCO '16 Amsterdam
2016
P017: Periostin aggravates the development of colitis-associated colon cancer in miceECCO '16 Amsterdam
2016
P018: Biologic functions between non-affected and affected margins of ileum samples from Crohn’s disease patients who will develop post-surgical recurrence.ECCO '16 Amsterdam
2016
P019: Informing ulcerative colitis pathophysiology and outcomes through metabolic pofilingECCO '16 Amsterdam
2016
P020: The efficacy of tofacitinib and a selective Janus kinase 1 inhibitor in dextran sulphate sodium colitis modelsECCO '16 Amsterdam
2016
P021: Inflammatory monocytes are key regulators of colonic inflammation in murine and human IBDECCO '16 Amsterdam
2016
P022: Parthenolide enhances the efficacy of anti-tumour effect of balsalazide in human colon cancer cells and colitis-associated colorectal cancer by blockade of NF-kB activationECCO '16 Amsterdam
2016